"A BMJ investigation reveals that the American Academy of Pediatrics' 2023 childhood obesity guidelines aggressively promote GLP-1 weight-loss drugs for children, despite undisclosed financial ties to the drugmakers. Over 20% of AAP leaders and more than a third of guideline committee members received payments from GLP-1 manufacturers, yet these conflicts of interest were not disclosed in the guidelines. The guidelines rely on limited, industry-funded evidence and overlook serious potential risks of GLP-1 drugs, while sidelining safer, lifestyle-based treatments for childhood obesity."
"The latest weight-loss craze-GLP-1 receptor agonists like Ozempic, Wegovy, and Mounjaro-is now shaping the medical guidelines used to treat children. A new BMJ investigation has found that the American Academy of Pediatrics (AAP)'s 2023 childhood obesity guidelines-already controversial for recommending weight-loss drugs for kids as young as eight-are riddled with undisclosed financial ties to the very companies making these injections. The study's authors warn that these conflicts, combined with irregularities in how the guidelines were developed, mean parents, doctors, and policymakers should view the AAP's recommendations with "extreme caution.""
AAP 2023 childhood obesity guidelines recommend offering GLP-1 receptor agonist weight-loss drugs to adolescents over 12 and consider them for children aged 8–11. More than 20% of AAP leaders and over one-third of guideline committee members received payments from GLP-1 manufacturers that were not disclosed in the guidelines. The guidelines rely heavily on limited, industry-funded evidence, understate potential risks and side effects, and de-emphasize lifestyle-based, nonpharmacologic treatments. Other countries recommend avoiding such drugs in children under 12 except in rare cases. Conflicts of interest and procedural irregularities warrant extreme caution from parents, clinicians, and policymakers.
Read at Natural Health News
Unable to calculate read time
Collection
[
|
...
]